Skip to main content

Table 3 Correlation between pre-treatment circulating angiogenesis-related biomarkers and survival outcomes in studies which recruited patients with metastatic colorectal cancer [22,23,24]

From: Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

Study Title No. of patients Treatment received Pre-treatment biomarker Correlation with survival outcomes
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapya [22] 582 FOLFOX or CAPOX chemotherapy + cediranib/placebo VEGF-D Low pre-treatment concentration correlated with improved PFS and OS regardless of treatment received
Ang2 No correlation
Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer [23] 90 Camptothecin VEGF-165 Patients with high pre-treatment concentration were more likely to have progressive disease during treatment
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [24] 43 FOLFIRI + bevacizumab VEGF-2 No correlation
  1. aAs part of the phase III, Horizon II trial